Ilaris Market Report 2026

Ilaris Market Overview

• The Ilaris market growth in the historic period has been driven by limited effectiveness of traditional anti inflammatory drugs, historical unmet needs in caps patients • Market expansion is supported by expansion of precision immunology research, increasing diagnosis of rare inflammatory diseases • Growth Driver: Impact Of Rising Prevalence Of Inflammatory Diseases On The Growth Of The Market • Market Trend: Innovative Biologic Therapies For Treating Inflammatory Conditions • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Ilaris Market?

Ilaris (canakinumab) is a monoclonal antibody medication used to treat a variety of inflammatory diseases, including certain rare autoinflammatory disorders. It works by targeting and inhibiting interleukin-1 beta (IL-1β), a cytokine involved in inflammatory responses. Ilaris is approved for conditions such as cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and systemic juvenile idiopathic arthritis (SJIA). By reducing inflammation, it helps prevent the severe symptoms and complications associated with these diseases, improving the quality of life for patients who do not respond to traditional treatments. The main types of patient demographics for ilaris include pediatric patients and adult patients. Pediatric patients are individuals under the age of 18, typically requiring specialized medical care tailored to their developmental stage. It is distributed through hospitals, specialty clinics, online pharmacies, and retail pharmacies and is applied for cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, gout, and other inflammatory conditions.

What Is The Ilaris Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of precision immunology research, increasing diagnosis of rare inflammatory diseases, growing biologics reimbursement coverage, advancements in cytokine targeting therapies, growth of specialty rheumatology centers. Major trends in the forecast period include expansion of il-1 targeted therapies, rising focus on autoinflammatory disorders, growth in biologic treatments for rare diseases, increasing long term inflammation control, improved quality of life outcomes.

What Are The Drivers Of The Ilaris Market?

The rising prevalence of inflammatory diseases is expected to propel the growth of the ilaris market going forward. Inflammatory diseases are conditions in which the body's immune system triggers inflammation in tissues, resulting in pain, swelling, and potential damage. The rising prevalence of inflammatory diseases can be attributed to factors such as aging populations, environmental triggers, lifestyle changes, genetic predispositions, and an increase in autoimmune disorders. Ilaris is used to treat inflammatory diseases such as cryopyrin-associated periodic syndromes (CAPS) by inhibiting interleukin-1β, reducing inflammation and related symptoms. For instance, in September 2023, according to a report published by the National Library of Medicine (NLM), a US-based medical library, the incidence of inflammatory bowel disease (IBD) in Canada was 30 per 100,000, resulting in approximately 11,000 new diagnoses in 2023. The incidence is expected to increase by 0.58% annually, reaching 32.1 per 100,000 by 2035. Therefore, the rising prevalence of inflammatory diseases is driving the growth of the ilaris industry. The rising geriatric population is expected to boost the growth of the ilaris market going forward. The geriatric population refers to a demographic group characterized by a higher proportion of individuals aged 65 and older, often due to increased life expectancy and declining birth rates. The geriatric population is increasing due to advancements in healthcare and living standards that extend life expectancy, combined with declining birth rates in many regions. Ilaris is essential for the geriatric population as it offers an effective treatment for chronic inflammatory conditions, like gout flares and autoinflammatory diseases, in patients who may struggle with traditional therapies due to age-related health issues. For instance, in October 2024, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, the number of persons in the 60+ age group will increase from 1 billion in 2020 to 1.4 billion by 2030, making up one in six of the global population. It is predicted that there will be 2.1 billion persons 60 and older by 2050, which is a twofold increase. At the same time, the number of those 80 and older is predicted to treble, reaching 426 million. Therefore, the rising geriatric population will drive the ilaris industry.

Key Players In The Global Ilaris Market

Major companies operating in the ilaris market are Novartis AG

Global Ilaris Market Trends and Insights

The key trend in the ilaris market is developing innovative products, such as biologic therapies, to prevent, diagnose, or treat diseases. Biologic therapy utilizes substances derived from living organisms to treat diseases by specifically targeting components of the immune system. For instance, in August 2023, Novartis AG, a Switzerland-based pharmaceutical company, announced the U.S. Food & Drug Administration (FDA) approval for Ilaris (canakinumab) for treating gout flares in adults. This approval is intended for patients who cannot tolerate NSAIDs, colchicine, or repeated corticosteroid courses, or for whom these treatments are ineffective. As the first biologic therapy approved for gout flares, it provides a novel option for managing this painful condition. The decision was based on phase 3 clinical trials, which showed significant reductions in pain intensity and flare recurrence, with no unexpected safety issues reported.

What Defines the Ilaris Market?

The ilaris market consists of sales of secukinumab, erenumab, and dabrafenib. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ilaris Market Report 2026?

The ilaris market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ilaris industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.